Magnetic resonance imaging (MRI) reveals details of living tissues, diseased organs and tumors inside the body without X-rays or surgery. What if the same technology could peer down to the level of atoms? Doctors could make visual diagnoses of a person's molecules – examining damage on a strand of DNA, watching molecules misfold, or identifying a cancer cell by the proteins on its surface.

Diffusion abnormality index (DAI) shows promise as an imaging biomarker to measure brain tumor response to radiation therapy, according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North American (RSNA).

Bayer HealthCare announced that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

With radiation oncology treatments, the goal is to hit the tumor with as much ionizing X-ray energy as possible, while sparing adjacent, healthy tissue. The UC Davis Comprehensive Cancer Center has taken a major step toward that goal as one of the first sites in North America to install a sophisticated new multi-leaf collimator (MLC) system on its medical linear accelerators.

Konica Minolta Medical Imaging USA announced that it will collaborate with UMG / Del Medical, a leading provider of radiography products, to design a new DR system that will enhance the use of the Konica Minolta Aero DR flat panel technology when used in conjunction with a Del radiographic system. Once this project is completed, some Del Medical systems will allow seamless integration with the Konica Minolta Aero DR and provide cable-based communication for image transfer for both the X-ray table and upright Bucky systems. This configuration will also continuously charge the Aero DR panel, eliminating the need to remove the panel for charging.

CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium. This Symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

Neusoft Corporation announced that it has signed a Term Sheet with Philips on the proposed transaction of shares and assets in Philips and Neusoft Medical Systems Co. Ltd. ("PNMS"). According to the Term Sheet, Neusoft's wholly owned subsidiary Neusoft Medical System Co. Ltd. and its overseas associates intend to acquire 51 percent equities in PNMS held by Philips. Upon the completion of the proposed transaction, all intellectual property rights of PNMS will be shared by both Neusoft and Philips. In addition, a team of approximately 100 to 150 computed tomography (CT) system and component engineers and supporting staff will transfer from the joint venture to Philips.